Physician profile
Ryan Wallace
NPI 1689389868
$1,347.51
in general payments reported to CMS, 2019-2025
10 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $814 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.50 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $210.16 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $150.29 | 2024-2025 | Rexulti |
| Medical Device Business Services, INC. | $137.01 | 2025 | Stratafix |
| Agios Pharmaceuticals, INC. | $128.13 | 2025 | Pyrukynd |
| Genzyme Corporation | $125.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Airsupra |
| Boston Scientific Corporation | $125.00 | 2024 | |
| Ucb, INC. | $124.96 | 2024 | Nayzilam |
| Amgen INC. | $117.62 | 2025 | Krystexxa |
| Alkermes, INC. | $104.34 | 2024 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.